Chemosensitization of solid tumors by modulation of resistance mechanisms [0.03%]
通过调节耐药机制对实体瘤进行化学增敏
Ian A Cree,Louise Knight,Federica Di Nicolantonio et al.
Ian A Cree et al.
The number of drugs available for chemotherapy is growing exponentially, and this trend looks set to continue. Chemosensitization strategies use the administration of one drug or agent to render cancer cells more susceptible to a second age...
Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors [0.03%]
关于5-氮杂胞苷和5-氮杂-2'-脱氧胞苷治疗实体瘤的临床经验评述
Ana Aparicio,Jeffrey S Weber
Ana Aparicio
In recent years the importance of epigenetic changes in carcinogenesis has been unfolding. It is now clear that the fifth base of the genome, methylcytosine, plays a critical role in the control of gene expression during normal development ...
Gábor Varga
Gábor Varga
Dexloxiglumide, the (R)-isomer of loxiglumide, is a selective and highly potent CCK1 receptor antagonist. It is twice as potent as the racemic compound. because the anti-CCK activity is specific to the (R)-form, whereas the (S)-isomer is al...
Fabrizio De Ponti
Fabrizio De Ponti
Progenics is developing methylnaltrexone (MNTX), an opioid antagonist licensed from UR Labs and the University of Chicago, for the potential treatment of the side effects of opioid pain therapy, such as constipation and post-operative bowel...
Frank Sommer,Udo Engelmann
Frank Sommer
Bayer is developing vardenafil, an orally active phosphodiesterase (PDE) 5 inhibitor for the potential treatment of erectile dysfunction (ED) [314382]. NDAs were filed in September 2001 in the US and Mexico [423096], and vardenafil was subm...
Topiglan MacroChem [0.03%]
拓普甘宏化学有限公司
Chris G McMahon
Chris G McMahon
MacroChem is developing Topiglan, a topical gel containing prostaglandin E1 (PGE1 or alprostadil) and its patented through-the-skin absorption enhancer excipient (SEPA), for the potential treatment of erectile dysfunction. By September 2000...
Alessandro Lecci,Claudio Valenti,Carlo Alberto Maggi
Alessandro Lecci
Tachykinins (TKs) are abundantly expressed in the gastrointestinal (GI) tract in intrinsic excitatory motor neurons, interneurons, sensory neurons and extrinsic sensory neurons. Their role in the regulation of enteric secretomotor functions...
Christoph Beglinger
Christoph Beglinger
This review focuses on the satiating effect of cholecystokinin (CCK) in humans. Current evidence supports a role for the peptide as a physiological satiety factor. The therapeutic potential of CCK analogs cannot be estimated until further s...
Sarat C Chattaraj
Sarat C Chattaraj
United Therapeutics Corp (UTC) is developing treprostinil sodium (Remodulin, UT-15), a stable structural analog of prostacyclin, for the potential treatment of primary pulmonary (arterial) hypertension (PAH), peripheral vascular disease (PV...
Sampatrilat Shire [0.03%]
沙朴利特夏尔公司
Kristina Allikmets
Kristina Allikmets
Sampatrilat is a dual inhibitor of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE), which is under development by Pfizer and Shire (previously Roberts Pharmaceutical) for the potential treatment of hypertension. As of 19...